- Home
- BBIO vs MRNA Comparison
BBIO vs MRNA Comparison
Compare BBIO & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BBIO | MRNA |
|---|---|---|
| Founded | 2015 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 11.5B |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BBIO | MRNA |
|---|---|---|
| Price | $74.18 | $30.88 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 21 | 14 |
| Target Price | ★ $76.24 | $33.25 |
| AVG Volume (30 Days) | 2.0M | ★ 9.9M |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $353,780,000.00 | ★ $2,232,000,000.00 |
| Revenue This Year | $128.44 | N/A |
| Revenue Next Year | $76.14 | $0.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 62.46 | N/A |
| 52 Week Low | $25.34 | $22.28 |
| 52 Week High | $76.51 | $48.92 |
Technical Indicators
Market Signals| Indicator | BBIO | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 62.39 | 72.36 |
| Support Level | $72.73 | $28.66 |
| Resistance Level | $76.51 | $30.44 |
| Average True Range (ATR) | 2.37 | 1.30 |
| MACD | -0.30 | 0.52 |
| Stochastic Oscillator | 66.40 | 90.05 |
Price Performance
Historical ComparisonAbout BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.